Importantly, after being intravenously administered in HER2 reconstituted syngeneic mouse models, these primed MSC exhibit persistent localization at tumor areas, display markedly stronger immunoapoptotin staining and better anti-tumor effect in comparison with direct delivery of the purified immunoapoptotin or delivery by Jurkat cells, indicating that MSC mobility can be well extended for the specific killing of HER-2 overexpressed GC. Here, ERBB2 is linked to neoplasm.